Windlas Biotech Limited
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
What Windlas files
- Investor Meet58
- Others37
- Updates17
- Board Meeting10
- PPTs8
- Important6
Windlas Biotech kicked off FY27 with strong Q1 performance, achieving its 14th consecutive quarter of record revenue at **Rs 248 Cr, up 18% YoY**. Adjusted EBITDA grew **26% to Rs 34 Cr**, and adjusted PAT jumped **37% to Rs 25 Cr**, excluding non-cash ESOP expenses. EPS improved to **Rs 8.46**....
Windlas Biotech delivered strong FY26 results with revenue growing 19% YoY to Rs 904 Cr, marking its 13th consecutive quarter of record revenue. Adjusted EBITDA rose 26% to Rs 121 Cr, and Adjusted PAT increased 31% to Rs 83 Cr. EPS reached a post-listing high of Rs 31.60. The Generic...
1. **Business Performance:** Windlas Biotech hit its 12th consecutive record revenue quarter: Q3FY26 sales up 20% YoY to Rs 233 Cr. 9MFY26 revenue grew 19% YoY to Rs 666 Cr. Generic Formulations CDMO (+20% 9M, +23% Q3) and Exports (+29% 9M, +36% Q3) powered growth. 2. **Growth Drivers or Strategy:**...
Windlas Biotech delivered its 11th consecutive quarter of record revenue at Rs 222 Cr in Q2 FY26, with H1 FY26 revenue hitting a new high of Rs 432 Cr, both up 19% YoY. Generic Formulations CDMO (74% revenue, +18% YoY H1), Trade Generics (+25% YoY H1), and Exports (+23% YoY...
Here's a summary of the financial update: **Financial Highlights:** Windlas Biotech reported its 10th consecutive record quarter: Revenue hit Rs 210 Cr (+20% YoY), PAT rose 31% YoY to Rs 18 Cr (EPS Rs 8.4). EBITDA climbed 27% YoY to Rs 27 Cr, boosting margins to 12.6%. Gross margin expanded...